Graft-vs-Host disease treatment gets boost
The European Medicines Agency (EMA) has granted Israeli biotech Enlivex “orphan” status for its ApoCell treatment to prevent Graft-vs-Host Disease. It will speed up development of the Israeli innovation that stops rejection of transplanted cells and bone marrow.
This entry was posted in Israel's Medical Achievements
. Bookmark the permalink